Urine test to monitor for urothelial cancer recurrence
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study uses a urine test to detect small amounts of cancer DNA (microscopic residual disease) after treatment, to see if it can catch a recurrence earlier than standard scans or cystoscopy. It includes four groups of people with different types and stages of urothelial cancer (in the kidney, ureter, or bladder) to see how well the test works for each group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older, able to make your own medical decisions
- Has had surgery or treatment for urothelial cancer (cancer of the bladder, ureter, or kidney pelvis)
- You are willing to provide urine samples and undergo regular checkups (scans or cystoscopy) for at least one year
- No known active cancer spread (metastases) at the time of enrollment
- No other active cancer within the past 5 years (except for treated basal cell skin cancer or cervical carcinoma in situ)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new urine test that may help find cancers of the urinary tract (like bladder or kidney cancer) in people who have blood in their urine. If the test works well, it could provide a simpler way to check for cancer compared to standard procedures.
This study tests whether a simple urine test can accurately identify cancer in the bladder, ureters (tubes between kidneys and bladder), or renal pelvis (part of the kidney). You would provide urine samples before your planned surgery, and researchers will compare the urine test results to your actual tissue diagnosis after surgery.
This study uses a blood test to find and monitor urothelial cancer (a type of bladder cancer) and to watch for signs it may come back. It may help patients and doctors make better decisions about follow-up care.
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
This study tests a urine test that may help find bladder cancer early without needing invasive procedures. It is for people with high-grade or high-risk non-muscle-invasive bladder cancer who are receiving or have received BCG treatment.
This trial tests a new urine test (BCDx) to see if it can catch bladder cancer coming back in people with non-muscle invasive bladder cancer (NMIBC) who are already having regular check-ups. You would give a urine sample before your routine cystoscopy, and the results may help doctors monitor your cancer more easily.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.